Dexlansoprazole is a proton pump inhibitor (PPI) used to treat gastroesophageal reflux disease (GERD) and erosive esophagitis. It is available in delayed-release capsules, with a common dosage strength being 60 mg [1]. This formulation is designed to release medication at two distinct times during the day, providing prolonged acid suppression [2].
How does dexlansoprazole delayed-release work?
Dexlansoprazole delayed-release capsules contain dexlansoprazole, which works by irreversibly blocking the hydrogen-potassium adenosine triphosphatase (H+/K+-ATPase) enzyme system—commonly known as the proton pump—in gastric parietal cells [3]. This action reduces the amount of acid produced in the stomach, offering relief from symptoms associated with acid reflux and allowing damaged esophageal tissue to heal [2][3]. The dual delayed-release mechanism ensures that the active ingredient is released in both the small intestine and later in the stomach, contributing to sustained therapeutic levels [2].
What is the typical dosage of dexlansoprazole?
For the treatment of erosive esophagitis, the recommended dosage of dexlansoprazole delayed-release is 60 mg once daily for up to eight weeks [1]. For maintenance of healed erosive esophagitis, the dosage is typically 30 mg once daily [1]. If needed, doses of 60 mg once daily can be used for maintenance [1]. It is important to follow a healthcare provider's specific instructions regarding dosage and duration of treatment.
What is the difference between dexlansoprazole and other PPIs?
Dexlansoprazole is a dual delayed-release formulation, meaning it releases medication in two phases. This is distinct from many other proton pump inhibitors, which typically have a single release mechanism [2]. This dual release is intended to provide a longer duration of acid control compared to some other PPIs [2][4].
When does the patent for dexlansoprazole expire?
Patent information for pharmaceutical products can be complex and subject to change due to various legal challenges and exclusivities. For detailed and up-to-date information on dexlansoprazole patents and their expiration dates, resources like DrugPatentWatch.com can be consulted [5].
Are there generic versions of dexlansoprazole available?
The availability of generic versions of dexlansoprazole is dependent on patent expirations and regulatory approvals. Once patents expire and regulatory hurdles are cleared, generic manufacturers can produce and market their own versions of the drug [5]. Consumers may then see these available at a lower cost.
What are the potential side effects of dexlansoprazole?
Common side effects associated with dexlansoprazole use can include diarrhea, headache, nausea, abdominal pain, and flatulence [1]. More serious, though less common, side effects may occur, and patients should report any concerning symptoms to their doctor. Long-term use of PPIs like dexlansoprazole has also been associated with potential risks, such as an increased risk of fractures, low magnesium levels, and certain infections [3].
Who manufactures dexlansoprazole?
The original branded dexlansoprazole delayed-release capsules are manufactured by Takeda Pharmaceuticals [1]. Following patent expirations and the introduction of generics, other pharmaceutical companies may also produce and distribute dexlansoprazole.
Can dexlansoprazole be used for conditions other than GERD and erosive esophagitis?
While dexlansoprazole is FDA-approved for the treatment of GERD and healing erosive esophagitis, healthcare providers may prescribe it off-label for other conditions related to excessive stomach acid production, based on clinical judgment and available evidence [3].
---
1. Dexlansoprazole. (n.d.). Retrieved from https://www.nhs.uk/medicines/dexlansoprazole/
2. Dual Delayed Release Technology. (n.d.). Retrieved from https://www.dexilant.com/how-dexilant-works
3. Dexlansoprazole Oral Capsules. (n.d.). Retrieved from https://www.webmd.com/drugs/2/drug-152013/dexlansoprazole-delayed-release-oral/details
4. Product Information: Dexilant® (dexlansoprazole) delayed-release capsules. (n.d.). Retrieved from https://www.dexilant.com/prescribing-information
5. DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/